Continuous Glucose Monitor Patents

Continuous glucose monitor (CGM) patents cover enzyme-electrode sensor-chemistry innovations; factory-calibration and accuracy innovations; transmitter, insertion, and form-factor innovations; and implantable and optical-sensing innovations — with IP held by the CGM duopoly leaders, pump-integrated players, and implantable-sensor firms. MAJOR CGM PATENT HOLDERS: DEXCOM (large estate): transcutaneous amperometric glucose-oxidase sensor wire, no-fingerstick factory calibration, the G6/G7 10–15-day sensor, BLE transmitter and direct-to-phone, interference rejection (acetaminophen), and predictive/urgent-low alerts. ABBOTT (FreeStyle Libre, large estate): factory-calibrated 'wired-enzyme' technology (osmium-mediated glucose oxidase on the electrode), 14-day sensor, applicator, Libre 2/3 real-time and the small Libre 3 form factor. MEDTRONIC: Guardian/Simplera sensors, Enlite, integration with insulin pumps (closed-loop/automated insulin delivery), and predictive low-glucose suspend. SENSEONICS (Eversense): fully-implantable fluorescence-based sensor (boronic-acid chemistry) with a 180-day wear and an external transmitter. OTHERS: Roche, Ascensia/POCTech, Sibionics and Medtrum (emerging CGMs), and Apple (long-running non-invasive optical-glucose research). Dexcom and Abbott have litigated extensively against each other over sensor and calibration patents.

Glucose-sensing enzyme-electrode innovations; mediator and electron-transfer innovations; interference-rejection and membrane innovations; and biocompatibility/sensor-lifetime innovations represent core CGM patent domains — and the sensor chemistry plus membrane determine accuracy and wear time, the central CGM differentiators. ENZYME-ELECTRODE PATENTS: amperometric (electrochemical) glucose detection using glucose oxidase GOx or glucose dehydrogenase GDH immobilized on a working electrode, electrode materials (platinum, carbon), and enzyme immobilization chemistry. MEDIATOR / ELECTRON-TRANSFER PATENTS: redox mediators that shuttle electrons from enzyme to electrode (osmium complexes — Abbott's 'wired enzyme', ferrocene), reducing oxygen dependence and operating potential, and direct-electron-transfer designs. MEMBRANE PATENTS: diffusion-limiting membranes that linearize the glucose response and extend dynamic range, biocompatible outer membranes that reduce the foreign-body/fouling response (key to multi-day wear), and interference-blocking layers (rejecting acetaminophen, ascorbate, urate). LIFETIME / STABILITY PATENTS: anti-inflammatory and anti-fouling coatings, sensor drift compensation, and chemistry enabling 10–15-day (transcutaneous) or 180-day (implantable) wear. A stable, accurate, factory-calibratable enzyme-electrode-plus-membrane stack is the highest-value CGM IP because it sets accuracy (MARD) and wear duration.

Factory-calibration and accuracy-algorithm innovations; transmitter, wireless, and applicator innovations; implantable and optical-sensing innovations; and data/integration innovations represent additional CGM patent domains — though pure-algorithm claims face §101 scrutiny and pair with the sensor. CALIBRATION / ACCURACY PATENTS: factory (one-time, no-fingerstick) calibration enabled by tightly-controlled manufacturing, calibration-free sensor models, drift and temperature compensation, lag compensation (interstitial-to-blood glucose delay), and accuracy metrics (MARD mean absolute relative difference — the headline accuracy number, often ~8–10%). TRANSMITTER / FORM-FACTOR PATENTS: low-power BLE transmitter and direct-to-phone communication, integrated single-piece sensor-transmitter, one-button insertion applicator, adhesive and wear comfort, and water resistance. IMPLANTABLE / OPTICAL PATENTS: fully-implantable fluorescence sensing (boronic-acid glucose-binding fluorophore — Senseonics), optical/spectroscopic approaches (NIR, Raman, fluorescence) and the long-sought non-invasive glucose measurement. DATA / INTEGRATION PATENTS: predictive alerts and trend arrows, closed-loop integration with insulin pumps (automated insulin delivery algorithms), and remote/share monitoring. Calibration and accuracy algorithms are typically claimed together with the specific sensor and manufacturing to survive Alice/§101.

CGM startup IP strategy must navigate Dexcom and Abbott's deep sensor-chemistry and factory-calibration estates (and their mutual litigation history, which shows these patents are aggressively enforced), Medtronic pump-integration patents, Senseonics implantable-optical patents, decades of electrochemical-biosensor prior art, FDA Class III/De Novo regulatory requirements, and a §101 constraint on pure algorithms; understand that the durable IP is the specific enzyme-electrode chemistry, membrane, and factory-calibration-enabling manufacturing (hardware), that accuracy (MARD) and wear time are the competitive axes, and that FDA clearance is a parallel moat; identify whitespace in calibration-free chemistries, longer-wear and implantable sensors, multi-analyte (glucose + ketone/lactate) sensing, and genuinely non-invasive optical glucose. CGM STARTUP IP STRATEGY: SENSOR CHEMISTRY + MEMBRANE + FACTORY CALIBRATION ARE THE IP: patent the enzyme-electrode, mediator, diffusion-limiting/biocompatible membrane, and the manufacturing that enables no-fingerstick factory calibration — these set MARD and wear time; RESPECT THE DEXCOM/ABBOTT THICKET: the two leaders have sued each other repeatedly over sensor and calibration IP — run thorough FTO against both before building an amperometric CGM; ACCURACY + WEAR TIME ARE THE COMPETITIVE AXES: a sensor with lower MARD, longer wear (15-day+, implantable), and calibration-free operation is the commercial prize and strongest patent; MULTI-ANALYTE AND NON-INVASIVE ARE HIGHEST-VALUE WHITESPACE: glucose+ketone/lactate sensing and true non-invasive optical glucose (the holy grail Apple is chasing) are the least-consolidated terrain; FDA CLASS III/DE NOVO IS A PARALLEL MOAT: clearance gates competitors as much as IP; WHEN TO PATENT: NOVEL SENSOR WITH MEASURED ACCURACY: file once a sensor shows measured results (MARD % vs. reference, wear days, calibration-free operation, lag) — measured MARD, wear duration, calibration-free operation, and biocompatible lifetime are the critical CGM IP metrics; KEY FTO CHECKLIST: Dexcom transcutaneous glucose-oxidase factory-calibration 10-day BLE; Abbott FreeStyle Libre wired-enzyme osmium-mediator 14-day applicator; Medtronic Guardian/Enlite pump closed-loop; Senseonics implantable fluorescence boronic-acid 180-day; diffusion-limiting biocompatible membrane interference-rejection; MARD lag-compensation drift; amperometric biosensor prior art; non-invasive optical/Raman glucose; FDA Class III/De Novo.